Antagonistic Peptides That Specifically Bind to the First and Second Extracellular Loops of CCR5 and Anti-IL-23p19 Antibody Reduce Airway Inflammation by Suppressing the IL-23/Th17 Signaling Pathway

Asthma is a heterogeneous chronic inflammatory disorder of the airways with a complex etiology, which involves a variety of cells and cellular components. Therefore, the aim of the study was to investigate the effects and mechanisms of antagonistic peptides that specifically bind to the first and se...

Full description

Saved in:
Bibliographic Details
Main Authors: Yingli Zhang, Rongrong Liang, Aicen Xie, Wenqian Shi, Huarong Huang, Yingqiang Zhong
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Mediators of Inflammation
Online Access:http://dx.doi.org/10.1155/2020/1719467
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849692498654396416
author Yingli Zhang
Rongrong Liang
Aicen Xie
Wenqian Shi
Huarong Huang
Yingqiang Zhong
author_facet Yingli Zhang
Rongrong Liang
Aicen Xie
Wenqian Shi
Huarong Huang
Yingqiang Zhong
author_sort Yingli Zhang
collection DOAJ
description Asthma is a heterogeneous chronic inflammatory disorder of the airways with a complex etiology, which involves a variety of cells and cellular components. Therefore, the aim of the study was to investigate the effects and mechanisms of antagonistic peptides that specifically bind to the first and second extracellular loops of CCR5 (GH and HY peptides, respectively) and anti-interleukin-23 subunit p19 (anti-IL-23p19) in the airway and thereby mediate inflammation and the IL-23/T helper 17 (Th17) cell pathway in asthmatic mice. An experimental asthma model using BALB/c mice was induced by ovalbumin (OVA) and treated with peptides that are antagonistic to CCR5 or with anti-IL-23p19. The extents of the asthmatic inflammation and mucus production were assessed. In addition, bronchoalveolar lavage fluid (BALF) was collected, the cells were counted, and the IL-4 level was detected by ELISA. The IL-23/Th17 pathway-related protein and mRNA levels in the lung tissues were measured, and the positive production rates of Th17 cells in the thymus, spleen, and peripheral blood were detected. The groups treated with one of the two peptides and/or anti-IL-23p19 showed significant reductions in allergic inflammation and mucus secretion; decreased expression levels of IL-23p19, IL-23R, IL-17A and lactoferrin (LTF); and reduced proportions of Th17 cells in the thymus, spleen, and peripheral blood. Specifically, among the four treatment groups, the anti-IL-23p19 with HY peptide group exhibited the lowest positive production rate of Th17 cells. Our data also showed a significant and positive correlation between CCR5 and IL-23p19 protein expression. These findings suggest that the administration of peptides antagonistic to CCR5 and/or anti-IL-23p19 can reduce airway inflammation in asthmatic mice, most likely through inhibition of the IL-23/Th17 signaling pathway, and the HY peptide can alleviate inflammation not only through the IL-23/Th17 pathway but also through other mechanisms that result in the regulation of inflammation.
format Article
id doaj-art-ea7e25f964a14d608664f64faa89ac94
institution DOAJ
issn 0962-9351
1466-1861
language English
publishDate 2020-01-01
publisher Wiley
record_format Article
series Mediators of Inflammation
spelling doaj-art-ea7e25f964a14d608664f64faa89ac942025-08-20T03:20:40ZengWileyMediators of Inflammation0962-93511466-18612020-01-01202010.1155/2020/17194671719467Antagonistic Peptides That Specifically Bind to the First and Second Extracellular Loops of CCR5 and Anti-IL-23p19 Antibody Reduce Airway Inflammation by Suppressing the IL-23/Th17 Signaling PathwayYingli Zhang0Rongrong Liang1Aicen Xie2Wenqian Shi3Huarong Huang4Yingqiang Zhong5Department of Pediatrics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510120, ChinaDepartment of Pediatrics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510120, ChinaDepartment of Pediatrics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510120, ChinaDepartment of Pediatrics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510120, ChinaDepartment of Pediatrics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510120, ChinaDepartment of Gastroenterology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510120, ChinaAsthma is a heterogeneous chronic inflammatory disorder of the airways with a complex etiology, which involves a variety of cells and cellular components. Therefore, the aim of the study was to investigate the effects and mechanisms of antagonistic peptides that specifically bind to the first and second extracellular loops of CCR5 (GH and HY peptides, respectively) and anti-interleukin-23 subunit p19 (anti-IL-23p19) in the airway and thereby mediate inflammation and the IL-23/T helper 17 (Th17) cell pathway in asthmatic mice. An experimental asthma model using BALB/c mice was induced by ovalbumin (OVA) and treated with peptides that are antagonistic to CCR5 or with anti-IL-23p19. The extents of the asthmatic inflammation and mucus production were assessed. In addition, bronchoalveolar lavage fluid (BALF) was collected, the cells were counted, and the IL-4 level was detected by ELISA. The IL-23/Th17 pathway-related protein and mRNA levels in the lung tissues were measured, and the positive production rates of Th17 cells in the thymus, spleen, and peripheral blood were detected. The groups treated with one of the two peptides and/or anti-IL-23p19 showed significant reductions in allergic inflammation and mucus secretion; decreased expression levels of IL-23p19, IL-23R, IL-17A and lactoferrin (LTF); and reduced proportions of Th17 cells in the thymus, spleen, and peripheral blood. Specifically, among the four treatment groups, the anti-IL-23p19 with HY peptide group exhibited the lowest positive production rate of Th17 cells. Our data also showed a significant and positive correlation between CCR5 and IL-23p19 protein expression. These findings suggest that the administration of peptides antagonistic to CCR5 and/or anti-IL-23p19 can reduce airway inflammation in asthmatic mice, most likely through inhibition of the IL-23/Th17 signaling pathway, and the HY peptide can alleviate inflammation not only through the IL-23/Th17 pathway but also through other mechanisms that result in the regulation of inflammation.http://dx.doi.org/10.1155/2020/1719467
spellingShingle Yingli Zhang
Rongrong Liang
Aicen Xie
Wenqian Shi
Huarong Huang
Yingqiang Zhong
Antagonistic Peptides That Specifically Bind to the First and Second Extracellular Loops of CCR5 and Anti-IL-23p19 Antibody Reduce Airway Inflammation by Suppressing the IL-23/Th17 Signaling Pathway
Mediators of Inflammation
title Antagonistic Peptides That Specifically Bind to the First and Second Extracellular Loops of CCR5 and Anti-IL-23p19 Antibody Reduce Airway Inflammation by Suppressing the IL-23/Th17 Signaling Pathway
title_full Antagonistic Peptides That Specifically Bind to the First and Second Extracellular Loops of CCR5 and Anti-IL-23p19 Antibody Reduce Airway Inflammation by Suppressing the IL-23/Th17 Signaling Pathway
title_fullStr Antagonistic Peptides That Specifically Bind to the First and Second Extracellular Loops of CCR5 and Anti-IL-23p19 Antibody Reduce Airway Inflammation by Suppressing the IL-23/Th17 Signaling Pathway
title_full_unstemmed Antagonistic Peptides That Specifically Bind to the First and Second Extracellular Loops of CCR5 and Anti-IL-23p19 Antibody Reduce Airway Inflammation by Suppressing the IL-23/Th17 Signaling Pathway
title_short Antagonistic Peptides That Specifically Bind to the First and Second Extracellular Loops of CCR5 and Anti-IL-23p19 Antibody Reduce Airway Inflammation by Suppressing the IL-23/Th17 Signaling Pathway
title_sort antagonistic peptides that specifically bind to the first and second extracellular loops of ccr5 and anti il 23p19 antibody reduce airway inflammation by suppressing the il 23 th17 signaling pathway
url http://dx.doi.org/10.1155/2020/1719467
work_keys_str_mv AT yinglizhang antagonisticpeptidesthatspecificallybindtothefirstandsecondextracellularloopsofccr5andantiil23p19antibodyreduceairwayinflammationbysuppressingtheil23th17signalingpathway
AT rongrongliang antagonisticpeptidesthatspecificallybindtothefirstandsecondextracellularloopsofccr5andantiil23p19antibodyreduceairwayinflammationbysuppressingtheil23th17signalingpathway
AT aicenxie antagonisticpeptidesthatspecificallybindtothefirstandsecondextracellularloopsofccr5andantiil23p19antibodyreduceairwayinflammationbysuppressingtheil23th17signalingpathway
AT wenqianshi antagonisticpeptidesthatspecificallybindtothefirstandsecondextracellularloopsofccr5andantiil23p19antibodyreduceairwayinflammationbysuppressingtheil23th17signalingpathway
AT huaronghuang antagonisticpeptidesthatspecificallybindtothefirstandsecondextracellularloopsofccr5andantiil23p19antibodyreduceairwayinflammationbysuppressingtheil23th17signalingpathway
AT yingqiangzhong antagonisticpeptidesthatspecificallybindtothefirstandsecondextracellularloopsofccr5andantiil23p19antibodyreduceairwayinflammationbysuppressingtheil23th17signalingpathway